Senate Finance Committee leaders have responded to complaints by the chair of the American Heart Association's (AHA’s) Scientific Publishing Committee that they had unfairly singled out the AHA's journal, Circulation, for publishing a ghostwritten article (Haffner SM et al. Circulation. 2002;106:679-684). The 2002 article touted the benefits of rosiglitazone for lowering levels of certain biomarkers for cardiovascular risk in patients with type 2 diabetes.
Mitka M. Ghost Busting. JAMA. 2010;304(14):1546. doi:10.1001/jama.2010.1416